Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityPAR / Par Technology Corp. (698884103)
President & CEOFOLEY DONALD H
IndustryCalculating and Accounting Machines, Except Electronic Computers
Institutional Owners47
Institutional Shares6,545,977 - 40.71%
Common Shares Outstanding16,078,316 shares (as of 2018-03-31)
Institutional Value$ 72,241,000 USD

Institutional Stock Ownership and Shareholders()

PAR / Par Technology Corp. Institutional Ownership

Par Technology Corp. (NYSE:PAR) has 47 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 6,545,977 shares. Largest shareholders include Eliot Rose Asset Management Llc, Dimensional Fund Advisors Lp, Wellington Management Group LLP, Stone House Capital Management, LLC, Wedbush Securities Inc, Vanguard Group Inc, BlackRock Inc., BlackRock Institutional Trust Company, N.A., Renaissance Technologies LLC, and Thomson Horstmann & Bryant Inc.
Par Technology Corp. (NYSE:PAR) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/par"><img src="https://images.fintel.io/us-par-so.png" alt="PAR / Par Technology Corp. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 107,542 107,542 0.00 1,006 1,515 50.60
2017-10-26 13F-HR Acrospire Investment Management LLC 3,757 0 -100.00 32 0 -100.00
2017-11-09 13F-HR TFS CAPITAL LLC 22,286 0 -100.00 190 0 -100.00
2017-02-14 SC 13G/A ELIOT ROSE ASSET MANAGEMENT LLC 1,606,915 1,247,634 -22.36
2018-05-10 13F-HR Matarin Capital Management, LLC 11,167 0 -100.00 104,411 0 -100.00
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 30,335 30,335 0.00 284 427 50.35
2018-05-09 13F-HR BlackRock Inc. 273,221 268,031 -1.90 2,554 3,776 47.85
2018-05-15 13F-HR RBF Capital, LLC 70,685 70,685 0.00 661 996 50.68
2018-05-15 13F-HR Stone House Capital Management, LLC 675,000 750,000 11.11 6,311 10,568 67.45
2017-11-08 13F-HR Friedberg Investment Management 95,130 37,850 -60.21 810 395 -51.23
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 40,849 576
2018-05-14 13F-HR EAM Investors, LLC 0 10,100 0 142
2018-05-15 13F-HR PERRITT CAPITAL MANAGEMENT INC 123,248 0 -100.00 1,152 0 -100.00
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 27,309 27,309 0.00 255 384 50.59
2018-05-08 13F-HR O'SHAUGHNESSY ASSET MANAGEMENT, LLC 7,994 7,837 -1.96 75 110 46.67
2018-05-15 13F-HR Bank of New York Mellon Corp 12,463 15,641 25.50 116 220 89.66
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 10,789 152
2018-05-11 13F-HR Russell Investments Group, Ltd. 800 800 0.00 7 11 57.14
2018-05-15 13F-HR Wellington Management Group LLP 1,017,503 913,703 -10.20 9,514 12,874 35.32
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 0 2,200 0 31
2018-05-11 13F-HR GSA CAPITAL PARTNERS LLP 15,300 13,600 -11.11 143 192 34.27
2018-05-14 13F-HR ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 36,594 27,394 -25.14 342 386 12.87
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 0 81 0 1
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 407 505 24.08 4 7 75.00
2018-07-19 13F-HR Municipal Employees' Retirement System of Michigan 43,500 43,500 0.00 613 769 25.45
2018-05-11 13F-HR Tibra Equities Europe Ltd 22,719 320
2018-07-18 13F-HR Cornerstone Advisors, Inc. 21 21 0.00 2 2 0.00
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 837 714 -14.70 8 10 25.00
2018-05-15 13F-HR BARCLAYS PLC 34 4,034 11,764.71 0 56
2018-05-15 13F-HR Squarepoint Ops LLC 16,500 0 -100.00 154 0 -100.00
2018-05-14 13F-HR Renaissance Technologies LLC 227,100 166,300 -26.77 2,123 2,343 10.36
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 251,855 251,855 0.00 1,351 1,405 4.00
2018-05-04 13F-HR Granite Investment Partners, LLC 111,984 40,420 -63.91 1,047 569 -45.65
2018-05-07 13F-HR Sullivan, Bruyette, Speros & Blaney, Inc. 26,079 26,079 0.00 244 367 50.41
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 14,940 70,491 371.83 140 993 609.29
2018-05-15 13F-HR VANGUARD GROUP INC 400,082 432,739 8.16 3,741 6,098 63.00
2017-02-10 13F-HR BlackRock Advisors LLC 3,332 3,332 0.00 18 19 5.56
2018-05-14 13F-HR MORGAN STANLEY 636 3,332 423.90 6 47 683.33
2018-05-15 13F-HR UBS Group AG 0 2,601 0 37
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 10,876 10,329 -5.03 101 145 43.56
2018-05-10 13F-HR THOMSON HORSTMANN & BRYANT INC 0 165,190 0 2,327
2018-05-01 13F-HR WEDBUSH SECURITIES INC 489,734 454,616 -7.17 4,579 6,406 39.90
2018-06-20 13F-HR/A Brasada Capital Management, Lp 130,580 123,030 -5.78 1,141 1,733 51.88
2018-05-09 13F-HR NORTHERN TRUST CORP 51,059 46,612 -8.71 477 656 37.53
2018-05-02 13F-HR ALGERT GLOBAL LLC 237,219 88,440 -62.72 2,218 1,246 -43.82
2018-04-16 13F-HR Raymond James Financial Services Advisors, Inc. 28,000 395
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 921,978 921,226 -0.08 8,620 12,980 50.58
2017-02-10 13F-HR BlackRock Investment Management, LLC 1,764 1,764 0.00 9 10 11.11
2017-01-13 13F-HR MetLife Securities, Inc 3,000 0 -100.00 16 0 -100.00
2018-05-02 13F-HR THOMPSON DAVIS & CO., INC. 0 500 0 7
2017-02-10 13F-HR BlackRock Fund Advisors 27,365 28,161 2.91 147 157 6.80
2018-05-15 13F-HR DEUTSCHE BANK AG\ 48,100 15,998 -66.74 449 225 -49.89
2018-05-15 13F-HR BlueCrest Capital Management Ltd 21,767 11,089 -49.06 204 156 -23.53

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

PAR Technology's Emerging SaaS Businesses Could Be Gems

2018-07-07 seekingalpha
Based on the aggregate numbers, there is nothing to warrant such a rise; in fact, one could say quite the contrary. (24-1)

PAR Technology's (PAR) CEO Donald Foley on Q1 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Good day, ladies and gentlemen, and welcome to the PAR Technology Fiscal Year 2018 First Quarter Financial Conference Call. [Operator Instructions] As a reminder today's conference is being recorded. (6-0)

3 Reasons To Avoid PAR Technology

2018-03-31 seekingalpha
As I was reading Par Technology's (PAR) recent earnings call, something caught my eye--namely, this innocuous-sounding Q&A (italics added). (6-3)

Can PAR Technology's Share Rally Be Sustained?

2018-03-30 seekingalpha
After a period of mismanagement, the company is emerging with the first results of a new management, an acquisition, and a new strategy. (6-1)

PAR Technology's (PAR) CEO Donald Foley on Q4 2017 Results - Earnings Call Transcript

2018-03-15 seekingalpha
PAR Technology Corporation (NYSE:PAR) Q4 2017 Results Earnings Conference Call March 15, 2018 4:30 PM ET (6-0)

CUSIP: 698884103